Pollution from drug manufacturing: Review and perspectives

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1656, 2014, Pages

  Larsson, D G Joakim ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Environment; Management; Manufacture; Pharmaceuticals; Risk

Indexed keywords

CONCENTRATION (COMPOSITION); DRUG DEVELOPMENT; ENVIRONMENTAL ASSESSMENT; ENVIRONMENTAL RISK; INDUSTRIAL PRODUCTION; POLLUTION INCIDENCE;

INDUSTRIAL WASTE; WASTE WATER;

DRUG INDUSTRY; INDUSTRIAL WASTE; POLLUTION; SEWAGE; WASTE WATER;

DRUG INDUSTRY; ENVIRONMENTAL POLLUTION; INDUSTRIAL WASTE; WASTE DISPOSAL, FLUID; WASTE WATER;

EID: 84907855454     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0571     Document Type: Review

References (70)

1. Bisarya S, Patil D. 1993 Determination of salicylicacid and phenol (ppm level) in effluent from aspirin plant. Res. Ind. 38, 170-172.
2. Holm JV, Ruegge K, Bjerg PL, Christensen TH. 1995 Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grindsted, Denmark). Environ. Sci. Technol. 29, 1415-1420. (doi: 10. 1021/es00005a039).
3. Reddersen K, Heberer T, Dunnbier U. 2002 Identification and significance of phenazone drugs and their metabolites in ground-and drinking water. Chemosphere 49, 539-544. (doi: 10. 1016/S0045-6535(02)00387-9).
4. Zühlke S, Dünnbier U, Heberer T. 2004 Detection and identification of phenazone-type drugs and their microbial metabolites in ground and drinking water applying solid-phase extraction and gas chromatography with mass spectrometric detection. J. Chromatogr. A 1050, 201-209. (doi: 10. 1016/j. chroma. 2004. 08. 051).
5. Lee WY, Arnold CR. 1983 Chronic toxicity of oceandumped pharmaceutical wastes to the marine amphipod Amphithoe valida. Mar. Pollut. Bull. 14, 150-153. (doi: 10. 1016/0025-326x(83)90070-X).
6. Qiting J, Xiheng Z. 1988 Combination process of anaerobic digestion and ozonation technology for treating wastewater from antibiotics production. Water Treat 3, 285-291.
7. Williams RT. 2005 Human health pharmaceuticals in the environment: an introduction. In Human pharmaceuticals: assessing the impacts on aquatic ecosystems (ed. RT Williams), pp. 1-46. Pensacola, FL: Society of Environmental Toxicology and Chemistry.
8. Amt für Umwelt und Energie Basel-Stadt 2004 Rhein-überwachtungs-Station Weil am Rhein. Jahresbericht 2003. See http://www. aue. bs. ch/jb_2003. pdf.
9. Norwegian Environment Agency 2005 See http://www. miljodirektoratet. no/no/Nyheter/Nyheter/Oldklif/2005/September/Nye_antibiotikautslipp_fra_Alpharma_i_Oslo/.
10. Cui CW, Ji SL, Ren HY. 2006 Determination of steroid estrogens in wastewater treatment plant of a contraceptives producing factory. Environ. Monit. Assess. 121, 409-419. (doi: 10. 1007/s10661-005-9139-8).
11. Larsson DGJ, de Pedro C, Paxéus N. 2007 Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard. Mater. 148, 751-755. (doi: 10. 1016/j. jhazmat. 2007. 07. 008).
12. Li D, Yang M, Hu J, Ren L, Zhang Y, Li K. 2008 Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ. Toxicol. Chem. 27, 80-86. (doi: 10. 1897/07-080. 1).
13. Lin AY, Yu TH, Lin CF. 2008 Pharmaceutical contamination in residential, industrial, and agricultural waste streams: risk to aqueous environments in Taiwan. Chemosphere 74, 131-141. (doi: 10. 1016/j. chemosphere. 2008. 08. 027).
14. Babic S, Mutavdzic D, Asperger D, Horvat AJM, Kastelan-Macan M. 2007 Determination of veterinary pharmaceuticals in production wastewater by HPTLC-videodensitometry. Chromatographia 65, 105-110. (doi: 10. 1365/s10337-006-0109-2).
15. Li D, Yang M, Hu J, Zhang Y, Chang H, Jin F. 2008 Determination of penicillin G and its degradation products in a penicillin production wastewater treatment plant and the receiving river. Water Res. 42, 307-317. (doi: 10. 1016/j. watres. 2007. 07. 016).
16. Lin AY, Tsai YT. 2009 Occurrence of pharmaceuticals in Taiwan's surface waters: impact of waste streams from hospitals and pharmaceutical production facilities. Sci. Total Environ. 407, 3793-3802. (doi: 10. 1016/j. scitotenv. 2009. 03. 009).
17. Fick J, Soderstrom H, Lindberg RH, Phan C, Tysklind M, Larsson DGJ. 2009 Contamination of surface, ground, and drinking water from pharmaceutical production. Environ. Toxicol. Chem. 28, 2522-2527. (doi: 10. 1897/09-073. 1).
18. Prasse C, Schlusener MP, Schulz R, Ternes TA. 2010 Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ. Sci. Technol. 44, 1728-1735. (doi: 10. 1021/es903216p).
19. Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B. 2010 Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ. Sci. Technol. 44, 4910-4916. (doi: 10. 1021/es100356f).
20. Kristiansson E, Fick J, Janzon A, Grabic R, Rutgersson C, Weijdegård B, Söderström H, Larsson DGJ. 2011 Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS ONE 6, e17038. (doi: 10. 1371/journal. pone. 0017038).
21. Sim W-J, Lee J-W, Lee E-S, Shin S-K, Hwang S-R, Oh J-E. 2011 Occurrence and distribution of pharmaceuticals in wastewater from households, livestock farms, hospitals and pharmaceutical manufactures. Chemosphere 82, 179-186. (doi: 10. 1016/j. chemosphere. 2010. 10. 026).
22. Gasser G, Pankratov I, Elhanany S, Werner P, Gun J, Gelman F, Lev O. 2012 Field and laboratory studies of the fate and enantiomeric enrichment of venlafaxine and O-desmethylvenlafaxine under aerobic and anaerobic conditions. Chemosphere 88, 98-105. (doi: 10. 1016/j. chemosphere. 2012. 02. 074).
23. Lester Y, Mamane H, Zucker I, Avisar D. 2013 Treating wastewater from a pharmaceutical formulation facility by biological process and ozone. Water Res. 47, 4349-4356. (doi: 10. 1016/j. watres. 2013. 04. 059).
24. Khan GA, Berglund B, Khan KM, Lindgren PE, Fick J. 2013 Occurrence and abundance of antibiotics and resistance genes in rivers, canal and near drug formulation facilities: a study in Pakistan. PLoS ONE 8, e62712. (doi: 10. 1371/journal. pone. 0062712).
25. Rutgersson C et al. 2014 Fluoroquinolones and qnr genes in sediment, water, soil, and human fecal flora in an environment polluted by manufacturing discharges. Environ. Sci. Technol. 48, 7825-7832. (doi: 10. 1021/es501452a).
26. Collado N, Rodriguez-Mozaz S, Gros M, Rubirola A, Barcelo D, Comas J, Rodriguez-Roda I, Buttiglieri G. 2014 Pharmaceuticals occurrence in a WWTP with significant industrial contribution and its input into the river system. Environ. Pollut. 185, 202-212. (doi: 10. 1016/j. envpol. 2013. 10. 040).
27. Oaks JL et al. 2004 Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427, 630-633. (doi: 10. 1038/nature02317).
28. Lindberg RH, Wennberg P, Johansson MI, Tysklind M, Andersson BA. 2005 Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatment plants in Sweden. Environ. Sci. Technol. 39, 3421-3429. (doi: 10. 1021/es048143z).
29. Lubick N. 2009 India's drug problem. Nature 457, 640-641. (doi: 10. 1038/457640a).
30. Mason M. 2009 World's highest drug levels entering India stream. Jakarta Post, 26 January 2009. See http://www. thejakartapost. com/news/2009/01/26/world039s-highest-drug-levels-entering-indiastream. html.
31. Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, Flick RW. 2007 Collapse of a fish population after exposure to a synthetic estrogen. Proc. Natl Acad. Sci. USA 104, 8897-8901. (doi: 10. 1073/pnas. 0609568104).
32. Taylor D. 2010 Ecopharmacostewardship: a pharmaceutical industry perspective. In Green and sustainable pharmacy (eds K Kümmerer, M Hempel), pp. 105-126. Berlin, Germany: Springer.
33. Soulet B, Tauxe A, Tarradellas J. 2002 Analysis of acidic drugs in Swiss wastewaters. Int. J. Environ. Anal. Chem. 82, 659-667. (doi: 10. 1080/0306731021000075384).
34. Hoerger CC, Dorr B, Schlienger C, Straub JO. 2009 Environmental risk assessment for the galenical formulation of solid medicinal products at Roche Basle, Switzerland. Integr. Environ. Assess. Manag. 5, 331-337. (doi: 10. 1897/IEAM_2008-049. 1).
35. Rutgersson C, Gunnarsson L, Fick J, Kristiansson E, Larsson DGJ. 2013 Oral exposure to industrial effluent with exceptionally high levels of drugs does not indicate acute toxic effects in rats. Environ. Toxicol. Chem. 32, 577-584. (doi: 10. 1002/etc. 2105).
36. Peele ER, Singleton FL, Deming JW, Cavari B, Colwell RR. 1981 Effects of pharmaceutical wastes on microbial-populations in surface waters at the Puerto-Rico dump site in the Atlantic-Ocean. Appl. Environ. Microbiol. 41, 873-879.
37. Guardabassi L, Petersen A, Olsen JE, Dalsgaard A. 1998 Antibiotic resistance in Acinetobacter spp. isolated from sewers receiving waste effluent from a hospital and a pharmaceutical plant. Appl. Environ. Microbiol. 64, 3499-3502.
38. Guardabassi L, Dalsgaard A, Olsen JE. 1999 Phenotypic characterization and antibiotic resistance of Acinetobacter spp. isolated from aquatic sources. J. App. Microbiol. 87, 659-667. (doi: 10. 1046/j. 1365-2672. 1999. 00905. x).
39. Gerhardt A, de Bisthoven LJ, Mo Z, Wang C, Yang M, Wang Z. 2002 Short-term responses of Oryzias latipes (Pisces: Adrianichthyidae) and Macrobrachium nipponense (Crustacea: Palaemonidae) to municipal and pharmaceutical waste water in Beijing, China: survival, behaviour, biochemical biomarkers. Chemosphere 47, 35-47. (doi: 10. 1016/S0045-6535(01)00223-5).
40. Zhao D et al. 2007 Toxicity of pharmaceutical wastewater on male reproductive system of Mus musculus. Toxicol. Ind. Health 23, 47-54. (doi: 10. 1177/0748233707077446).
41. Tisler TZ-KJ. 2007 The 'whole-effluent' toxicity approach. Int. J. Environ. Pollut. 31, 3-12. (doi: 10. 1504/Ijep. 2007. 015658).
42. Li D, Yang M, Hu J, Zhang J, Liu R, Gu X, Zhang Y, Wang Z. 2009 Antibiotic-resistance profile in environmental bacteria isolated from penicillin production wastewater treatment plant and the receiving river. Environ. Microbiol. 11, 1506-1517. (doi: 10. 1111/j. 1462-2920. 2009. 01878. x).
43. Gunnarsson L, Kristiansson E, Rutgersson C, Sturve J, Fick J, Forlin L, Larsson DGJ. 2009 Pharmaceutical industry effluent diluted 1: 500 affects global gene expression, cytochrome P450 1A activity, and plasma phosphate in fish. Environ. Toxicol. Chem. 28, 2639-2647. (doi: 10. 1897/09-120. 1).
44. Carlsson G, Örn S, Larsson DGJ. 2009 Effluent from bulk drug production is toxic to aquatic vertebrates. Environ. Toxicol. Chem. 28, 2656-2662. (doi: 10. 1897/08-524. 1).
45. Li D, Yu T, Zhang Y, Yang M, Li Z, Liu M, Qi R. 2010 Antibiotic resistance characteristics of environmental bacteria from an oxytetracycline production wastewater treatment plant and the receiving river. Appl. Environ. Microbiol. 76, 3444-3451. (doi: 10. 1128/AEM. 02964-09).
46. Sanchez W et al. 2011 Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ. Int. 37, 1342-1348. (doi: 10. 1016/j. envint. 2011. 06. 002).
47. Li D, Qi R, Yang M, Zhang Y, Yu T. 2011 Bacterial community characteristics under long-term antibiotic selection pressures. Water Res. 45, 6063-6073. (doi: 10. 1016/j. watres. 2011. 09. 002).
48. Beijer K, Gao K, Jönsson ME, Larsson DGJ, Brunström B, Brandt I. 2013 Effluent from drug manufacturing affects cytochrome P450 1 regulation and function in fish. Chemosphere 90, 1149-1157. (doi: 10. 1016/j. chemosphere. 2012. 09. 023).
49. Marathe NP, Regina VR, Walujkar SA, Charan SS, Moore ERB, Larsson DGJ, Shouche YS. 2013 A treatment plant receiving waste water from multiple bulk drug manufacturers is a reservoir for highly multi-drug resistant integron-bearing bacteria. PLoS ONE 8, e77310. (doi: 10. 1371/journal. pone. 0077310).
50. Johnning A, Moore ER, Svensson-Stadler L, Shouche YS, Larsson DGJ, Kristiansson E. 2013 Acquired genetic mechanisms of a multiresistant bacterium isolated from a treatment plant receiving wastewater from antibiotic production. Appl. Environ. Microbiol. 79, 7256-7263. (doi: 10. 1128/AEM. 02141-13).
51. Norwegian Environment Agency 2013 See http://www. miljodirektoratet. no/no/Nyheter/Nyheter/2013/Desember/Millionbot-etter-fiskedod-i-Oslo/.
52. Wang FQ, Zhang CG, Li B, Wei DZ, Tong WY. 2009 New microbiological transformations of steroids by Streptomyces virginiae IBL-14. Environ. Sci. Technol. 43, 5967-5974. (doi: 10. 1021/es900585w).
53. Zhang T, Zhang XX, Ye L. 2011 Plasmid metagenome reveals high levels of antibiotic resistance genes and mobile genetic elements in activated sludge. PLoS ONE 6, e26041. (doi: 10. 1371/journal. pone. 0026041).
54. Liu M, Zhang Y, Yang M, Tian Z, Ren L, Zhang S. 2012 Abundance and distribution of tetracycline resistance genes and mobile elements in an oxytetracycline production wastewater treatment system. Environ. Sci. Technol. 46, 7551-7557. (doi: 10. 1021/es301145m).
55. Ashbolt NJ et al. 2013 Human health risk assessment (HHRA) for environmental development and transfer of antibiotic resistance. Environ. Health Perspect. 121, 993-1001. (doi: 10. 1289/ehp. 1206316).
56. Finley RL et al. 2013 The scourge of antibiotic resistance: the important role of the environment. Clin. Infect. Dis. 57, 704-710. (doi: 10. 1093/cid/cit355).
57. Pruden A et al. 2013 Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ. Health Perspect. 121, 878-885. (doi: 10. 1289/ehp. 1206446).
58. Greenpeace. 2004 State of community health at Medak district, pp. 1-69. Bangalore, India: Greenpeace India.
59. Kookana RS et al. 2014 Potential ecological footprints of active pharmaceutical ingredients: an examination of risk factors in low-, middleand high-income countries. Phil. Trans. R. Soc. B 369, 20130586. (doi: 10. 1098/rstb. 2013. 0586).
60. Murray-Smith RJ, Coombe VT, Gronlund MH, Waern F, Baird JA. 2012 Managing emissions of active pharmaceutical ingredients from manufacturing facilities: an environmental quality standard approach. Integr. Environ. Assess. Manag. 8, 320-330. (doi: 10. 1002/ieam. 1268).
61. Roos V, Gunnarsson L, Fick J, Larsson DGJ, Ruden C. 2012 Prioritising pharmaceuticals for environmental risk assessment: towards adequate and feasible first-tier selection. Sci. Total Environ. 421-422, 102-110. (doi: 10. 1016/j. scitotenv. 2012. 01. 039).
62. Environmental Performance Index 2014 Water Resources. See http://epi. yale. edu/our-methods/water-resources.
63. Larsson DGJ, Fick J. 2009 Transparency throughout the production chain-a way to reduce pollution from the manufacturing of pharmaceuticals? Regul. Toxicol. Pharm. 53, 161-163. (doi: 10. 1016/j. yrtph. 2009. 01. 008).
64. Ihos M, Lazau C, Manea F. 2013 DSA electrodes for treating pharmaceutical effluents. Environ. Eng. Manag. J. 12, 901-905.
65. European Union 2013 Directive 2013/39/EU of the European Parliament and of the Council of 12 August 2013 amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in the field of water policy. Official Journal of the European Union L226, 1-17. See http://eur-lex. europa. eu/LexUriServ/LexUriServ. do?uri=OJ: L: 2013: 2226: 0001: 0017: EN: PDF.
66. Tello A, Austin B, Telfer TC. 2012 Selective pressure of antibiotic pollution on bacteria of importance to public health. Environ. Health Perspect. 120, 1100-1106. (doi: 10. 1289/ehp. 1104650).
67. European Medical Agency 2006 Guideline on the environmental risk assessment of medicinal products for human use. See http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003978. pdf.
68. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 1998 Environmental Assessment of Human Drug and Biologics Applications. See http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070561. pdf.
69. BIO Intelligence Service 2013 Study on the environmental risks of medicinal products, Final Report prepared for Executive Agency for Health and Consumers. See http://ec. europa. eu/health/files/environment/study_environment. pdf.
70. Larsson DGJ. 2010 Release of active pharmaceutical ingredients from manufacturing sites: need for new management strategies. Integr. Environ. Assess. Manag. 6, 184-186. (doi: 10. 1002/ieam. 20).